P-glycoprotein function in peripheral T lymphocyte subsets of myasthenia gravis patients: Clinical implications and influence of glucocorticoid administration

International Immunopharmacology

Volumn 9, Issue 3, 2009, Pages 284-290

  Tanaka, Sachiko ^a   Masuda, Masayuki ^b   Nakajima, Kanako ^a   Ido, Nobuhiro ^b   Ohtsuka, Takao ^b   Nishida, Masashi ^b   Utsumi, Hiroya ^b   Hirano, Toshihiko ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Glucocorticoid therapy; Myasthenia gravis; P glycoprotein; Peripheral blood mononuclear cells

Indexed keywords

CHOLINESTERASE INHIBITOR; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; PREDNISOLONE; RHODAMINE 123;

ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CORTICOSTEROID THERAPY; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; P-GLYCOPROTEIN; PREDNISOLONE; T-LYMPHOCYTE SUBSETS; THYMECTOMY;

EID: 60249092359     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.11.007     Document Type: Article

References (38)

1. Vicent A., Palace J., and Hilton J.D. Myasthenia gravis. Lancet 357 (2001) 2122-2128
2. Brocke S., Brautbar C., Steinman L., Abramsky O., Rothbard J., Neumann D., et al. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest 82 (1988) 894-900
3. Harcourt G.C., Sommer N., Rothbard J., Willcox H.N., and Newsom-Davis J. A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis. J Clin Invest 82 (1988) 1295-1300
4. Zhang G.X., Ma C.G., Xiao B.G., Bakhiet M., Link H., and Olsson T. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats. Eur J Immunol 25 (1995) 1191-1198
5. Crosti F., Armanini M., Confalonieri P., Antozzi C., and Mantegazza R. Changes in peripheral blood lymphocyte subset frequencies in myasthenia gravis patients are related to immunosuppression. J Neurol 241 (1994) 218-1192
6. Chavis P.S., Stickler D.E., and Walker A. Immunosuppressive or surgical treatment for ocular Myasthenia Gravis. Arch Neurol 64 (2007) 1792-1794
7. Rivner M.H. Steroid treatment for myasthenia gravis: steroids are overutilized. Muscle Nerve 25 (2002) 115-117
8. Ueda K., Cornwell M.M., Gottesman M.M., Pastan I., Roninson I.B., Ling V., et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 141 (1986) 956-962
9. Chaudhary P.M., Mechetner E.B., and Roninson I.B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80 (1992) 2735-2739
10. Ueda K., Okamura N., Hirai M., Tanigawara Y., Saeki T., Kioka N., et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267 (1992) 24248-24252
11. Marie J.P., Huet S., Faussat A.M., Perrot J.Y., Chevillard S., Barbu V., et al. Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris. Leukemia 11 (1997) 1086-1094
12. Leith C.P., Chen I.M., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E., et al. Correlation of multidrug resistance (MDR1) protein expression with functionaldye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux-cases. Blood 86 (1995) 2329-2342
13. Ludescher C., Thaler J., Drach D., Drach J., Spitaler M., Gattringer C., et al. Detection of activity of P-glycoprotein in human tumour samples using rhodamine 123. Br Haematol 82 (1992) 161-168
14. Yvonne R.P., Felipe V.B., Antonio V., and Luis L. Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. Biomed Pharmacother 58 (2004) 320-324
15. Maillefert J.F., Maynadie M., Tebib J.G., Aho S., Walker P., Chatard C., et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 35 (1996) 430-435
16. Hirano T., Onda K., Toma T., Miyaoka M., Moriyasu F., and Oka K. MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration. J Clin Pharmacol 44 (2004) 481-486
17. Wolfe G.I., Herbelin L., Nations S.P., Foster B., Bryan W.W., and Barohn R.J. Myasthenia gravis activities of daily living profile. Neurology 52 (1999) 1487-1489
18. Hirano T., Oka K., Umezawa Y., Hirata M., Ohi T., and Koga M. Individual pharmacodynamics assessed by antilymphocyte action predicts clinical cyclosporine efficacy in psoriasis. Clin Pharmcol Ther 63 (1998) 465-470
19. Goda K., Fenyvesi F., Bacsó Z., Nagy H., Márián T., Megyeri A., et al. Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody. J Pharmacol Exp Ther 320 (2007) 81-88
20. Donnenberg V.S., Burckart G.J., Zeevi A., Griffith B.P., Iacono A., McCurry K.R., et al. P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejection. Transplantation 77 (2004) 1699-1706
21. Donnenberg V.S., Wilson J.W., Burckart G.J., Zeevi A., Iacono A., and Donnenberg A.D. Measurement of basal, substrate induced and total P-glycoprotein activity in bronchoalveolar lavage T-cell subsets. Cytometry A 57 (2004) 75-85
22. Young I.T. Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 25 (1977) 935-941
23. Besinger U.A., Toyka K.V., Hömberg M., Heininger K., Hohlfeld R., and Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33 (1983) 1316-1321
24. Karagiannidis C., Rückert B., Hense G., Willer G., Menz G., Blaser K., et al. Distinct leucocyte redistribution after glucocorticoid treatment among difficult to treat asthmatic patients. Scand J Immunol 61 (2005) 187-196
25. Bock H.A. Steroid-resistant kidney transplant rejection: diagnosis and treatment. J Am Soc Nephrol 12 (2001) S48-S52
26. Milani M., Ostlie N., Wu H., Wang W., and Conti-Fine B.M. CD4+ T and B cells cooperate in the immunoregulation of experimental autoimmune myasthenia gravis. J Neuroimmunol 179 (2006) 152-162
27. Drach J., Gsur A., Hamilton G., Zhao S., Angerler J., Fiegl M., et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2(IL-2), IL-4, and interferon- gamma in normal human T lymphocytes. Blood 88 (1996) 1747-1754
28. Tsujimura S., Saito K., Nakayamada S., Nakano K., Tsukada J., Kohno K., et al. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 9 (2004) 1265-1273
29. Pavek P., Cerveny L., Svecova L., Brysch M., Libra A., Vrzal R., et al. Examination of Glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines. Placenta 28 (2007) 1004-1011
30. Chaudhary P.M., Mechetner E.B., and Roninson I.B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80 (1992) 2735-2739
31. Ju S.T., Panka D.J., Cui H., Ettinger R., el-Khatib M., Sherr D.H., et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373 (1995) 444-448
32. Yang Y., Merćep M., Ware C.F., and Ashwell J.D. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas:inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J Exp Med 181 (1995) 1673-1682
33. Gollapud S., and Gupta S. Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol 21 (2001) 420-430
34. Gupta S., Kim C.H., Tsuruo T., and Gollapudi S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol 12 (1992) 451-458
35. Saeki T., Ueda K., Tanigawara Y., Hori R., and Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268 (1993) 6077-6080
36. Sanders D.B., Aarli J.A., Cutter G.R., Jaretzki III A., Kaminski H.J., and Phillips II L.H. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 66 (2006) 954-955
37. Lavrnic D., Vujic A., Rakocevic-Stojanovic V., Stevic Z., Basta I., and Pavlovic S. Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand 111 (2005) 247-252
38. Tanaka S., Hirano T., Saito T., Wakata N., and Oka K. P-glycoprotein function in peripheral blood mononuclear cells of myasthenia gravis patients treated with tacrolimus. Biol Pharm Bull 30 (2007) 291-296